Grown Rogue International (GRUSF) Accumulated Expenses (2017 - 2024)
Grown Rogue International's (GRUSF) quarterly Accumulated Expenses came in at $2.1 million in Q4 2024, up 55.09% year-on-year from $1.4 million in Q1 2024, and up 55.09% quarter-over-quarter from $1.4 million in Q4 2023.
Grown Rogue International (GRUSF) Accumulated Expenses (2017 - 2024) Analysis & Trends
Grown Rogue International's Accumulated Expenses history runs 8 years deep, the most recent figure standing at $2.1 million for Q4 2024.
- On a quarterly basis, Accumulated Expenses rose 55.09% year-over-year to $2.1 million in Q4 2024; TTM through Dec 2024 was $2.1 million, a 55.09% increase from a year earlier, with the FY2024 full-year figure at $2.1 million, up 55.09% from the prior year.
- Accumulated Expenses improved to $2.1 million in Q4 2024 per GRUSF's latest filing, from $1.4 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $2.4 million in Q4 2023 and bottomed at -$10352.3 in Q4 2022.
- The 5-year median for Accumulated Expenses is $54944.0 (2020), against an average of $579962.1.
- Across the five-year window, Accumulated Expenses tumbled 396.93% in 2022 and soared 22894.42% in 2023, its largest moves.
- Year by year, Accumulated Expenses stood at $389816.0 in 2020, then plunged by 99.11% to $3486.4 in 2021, then sank by 396.93% to -$10352.3 in 2022, then jumped by 13227.14% to $1.4 million in 2023, then jumped by 55.09% to $2.1 million in 2024.
- Per Business Quant, the three latest GRUSF Accumulated Expenses figures stand at $2.1 million (Q4 2024), $1.4 million (Q4 2023), and $2.4 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Oct 31, 2023 | 2.36 Mn |
| Oct 31, 2022 | -10,352.31 |
| Oct 31, 2021 | 3,486.40 |
| Apr 30, 2021 | 6,250.00 |
| Jan 31, 2021 | 12,155.00 |
| Oct 31, 2020 | 389,816.00 |
| Jul 31, 2020 | 23,101.00 |
| Apr 30, 2020 | 54,944.00 |
| Jan 31, 2020 | 73,852.00 |
| Oct 31, 2019 | 180,799.00 |
| Jul 31, 2019 | 157,426.00 |
| Apr 30, 2019 | 158,673.00 |
| Jan 31, 2019 | 202,634.00 |
| Apr 30, 2018 | 468,310.00 |
| Oct 31, 2017 | 154,978.00 |